Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 2/20 | 0.46 |
| ▸ | DHODH | Q02127 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | TOP1 | P11387 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27783089 | 0.86 | SLC6A4 (0.54) | DHODHMAPTSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27992695 | 0.85 | PDE10A (0.53) | DHODHMAPTSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22406080 | 0.78 | KDM4E (0.46) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL398066 | 0.76 | NTRK1 (0.52) | CFTRDHODHMAPTKDM4EALDH1A1 | |
| SCHEMBL15665808 | 0.76 | ALDH1A1 (0.56) | DHODHMAPTKDM4EALDH1A1 | |
| SCHEMBL28480901 | 0.74 | PPARA (0.49) | SLC6A2SLC6A4SLC6A3KDM4ECNR1 | |
| SCHEMBL6637430 | 0.74 | MAPT (0.50) | CFTRMAPT | |
| SCHEMBL4206899 | 0.74 | TRPV1 (0.54) | CFTR | |
| SCHEMBL25149437 | 0.73 | CFTR (0.47) | CFTRDHODHMAPTKDM4EALDH1A1 | |
| SCHEMBL4849770 | 0.73 | TRPV1 (0.44) | CFTRDHODHKDM4ETOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390907-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20050153984-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153984-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CFTR 1816/4885DHODH 2323/4885MAPT 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.